Clinical trial Recruiting at 1 site Observational Ages 18 to 80

Using stereotactic radiotherapy for treating thoracic tumors

Official title: Safety and Efficacy of SBRT in the Treatment of Thoracic Malignant Tumors at Different Sites

Run by Peking University Third Hospital · NCT05349552 · Data updated 2026-11-12

This study tests if a special type of radiation therapy can safely treat chest tumors that are 5cm or smaller while protecting nearby healthy tissue.

Quick facts

Study typeObservational
Ages18 Years to 80 Years
SexAll
Enrollment120 (estimated)
SponsorPeking University Third Hospital
Academic / other
Drugs / interventionsradiation
Locations1 site (Beijing, Beijing Municipality)
StatusRecruiting
StartedMay 1, 2022
Main results expectedApril 30, 2025
Study endsApril 30, 2027
Registry record updatedDecember 27, 2023
Trial IDNCT05349552 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include patients with a pathological diagnosis of malignant tumors located in specific areas of the chest, with lesions measuring 5cm or less.

Probably not a fit

Patients with poor pulmonary function, severe underlying health conditions, or those unable to cooperate with treatment may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the safety and efficacy of stereotactic body radiation therapy (SBRT) for malignant tumors located in different areas of the chest. It categorizes tumors based on their proximity to critical structures such as the chest wall and bronchial tree, aiming to understand how these factors influence treatment outcomes and toxicity. The research focuses on patients with tumors that are 5cm or smaller and assesses the effectiveness of SBRT in providing localized control while minimizing damage to surrounding healthy tissue. By analyzing various tumor types, the study seeks to optimize treatment protocols for thoracic cancers.

Why it matters

Potential benefit: If successful, this study could enhance the safety and effectiveness of radiotherapy for patients with thoracic malignancies.

How similar studies have gone: Other studies have shown promising results with SBRT in lung cancer treatment, indicating potential success for this approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Pathological diagnosis was malignant tumor.
* The location of the target lesion belongs to one of five types and the lesion diameter is ≤ 5cm.
* There is no extensive systemic metastasis or although there is metastasis, the metastasis have been controlled by previous treatment.
* KPS\>70, no serious or uncontrolled underlying diseases, such as severe or uncontrolled hypertension, diabetes, cardiovascular and cerebrovascular diseases and organ dysfunction, and patients are expected to be tolerated by radiotherapy.

Exclusion Criteria:

* Poor basic pulmonary function or symptom correlation caused by various reasons, unable to lie flat or cooperate with treatment.
* The general condition is poor, and the expected survival time is less than 3 months.
* Psychiatric patients or poor compliance, unable to cooperate to complete treatment.
* For other reasons, the researcher believes that it is not suitable to participate in this trial.

Where it's running

  • Peking University Third Hospital
    Beijing, Beijing Municipality, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.